Vivos Therapeutics Inc
NASDAQ:VVOS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (12.9), the stock would be worth $-12.3 (1 294% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -1.1 | $1.03 |
0%
|
| Industry Average | 12.9 | $-12.3 |
-1 294%
|
| Country Average | 14.4 | $-13.7 |
-1 430%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Vivos Therapeutics Inc
NASDAQ:VVOS
|
11.1m USD | -1.1 | -0.6 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
98.3B USD | 14.1 | 55.6 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
69.3B EUR | 7.8 | 13.4 | |
| US |
|
Cigna Corp
NYSE:CI
|
72.9B USD | 0 | 12.2 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
24.4B EUR | 9.6 | 19.1 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23.2B EUR | 9.1 | 23.8 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
22.6B USD | 12.3 | 22.8 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
22.5B USD | 12.3 | 25.6 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.1B EUR | 5.4 | 11.2 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.8B USD | -31 | -28.4 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.3B USD | 7.1 | 13.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10 |
| Median | 14.4 |
| 70th Percentile | 21.5 |
| Max | 1 767 274.1 |
Other Multiples
Vivos Therapeutics Inc
Glance View
Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). The company is headquartered in Highlands Ranch, Colorado and currently employs 158 full-time employees. The company went IPO on 2020-12-11. The firm is focused on the development and commercialization to dental practices of a patented oral appliance technology and related protocols called the Vivos System. The firm's Vivos System is a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for people with sleep disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The Company’s business model is focused on dentists, and the Company’s program to train dentists and offer them other value-added services in connection with their ordering and use of the Vivos System for patients is called the Vivos Integrated Practice (VIP) program. Its primary product used in the Vivos System is the mRNA appliance, a specifically designed, custom oral appliance that is worn primarily in the evening hours and overnight and is available for adults.
